Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has shown a recent net value increase and varying returns over different time frames [1] - As of May 21, 2025, the latest net value of the fund is 1.6359 yuan, reflecting a growth of 1.36% [1] - The fund's one-month return is 4.85%, ranking 1834 out of 4645 in its category, while the three-month return is 0.17%, ranking 1678 out of 4590 [1] - Year-to-date, the fund has achieved a return of 4.28%, with a ranking of 2331 out of 4544 [1] Group 2 - The top ten stock holdings of the China Europe Medical Health Mixed A Fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%) and WuXi AppTec (9.95%) [1] - The fund was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.613 billion yuan [1] - The fund manager, Ge Lan, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in 2014 [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Innovation Stock A fund, which has shown significant growth in recent months and has a strong portfolio in the healthcare sector [1][3] - As of May 21, 2025, the latest net value of the fund is 1.3071 yuan, reflecting a growth of 2.38%. The fund's one-month return is 13.83%, six-month return is 19.76%, and year-to-date return is 25.71% [1] - The fund's top ten stock holdings account for a total of 75.62%, with notable investments in WuXi AppTec (10.35%), Kelun-Biotech (10.15%), and WuXi Biologics (9.82%) among others [1] Group 2 - The China Europe Medical Innovation Stock A fund was established on February 28, 2019, and as of March 31, 2025, it has a total scale of 4.675 billion yuan [1] - The fund is managed by Guo Lan, who has extensive experience in the investment management field, having held various positions in research and fund management since joining China Europe Fund Management in 2014 [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown a recent net value increase and varying returns over different time frames [1] - As of May 20, 2025, the fund's latest net value is 1.5473 yuan, reflecting a growth of 2.76% [1] - The fund's one-month return is 5.29%, three-month return is 0.92%, and year-to-date return is 2.57%, with respective rankings of 3149 out of 4647, 1587 out of 4590, and 3094 out of 4546 [1] Group 2 - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Kanglong Chemical (6.24%) [1] - The fund was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund manager, Ge Lan, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in 2014 [2]

Company Overview - Tiger Med's closing price on May 20 was 45.35 yuan, an increase of 6.76%, with a rolling PE ratio of 116.90 times and a total market value of 39.225 billion yuan [1] - The company ranks 42nd in the medical services industry, which has an average PE ratio of 38.49 times and a median of 39.26 times [1] - As of the first quarter of 2025, 80 institutions held shares in Tiger Med, including 78 funds, 1 social security fund, and 1 other entity, with a total holding of 170.6648 million shares valued at 8.671 billion yuan [1] Business Operations - Tiger Med is a Contract Research Organization (CRO) that provides comprehensive clinical research solutions for global pharmaceutical and medical device innovation companies [1] - The main services offered include clinical operations, clinical pharmacology, regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party audits and training, data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services [1] Financial Performance - In the first quarter of 2025, the company reported revenue of 1.564 billion yuan, a year-on-year decrease of 5.79%, and a net profit of 165 million yuan, down 29.61% year-on-year, with a gross profit margin of 30.03% [1]

每经编辑｜曾子建 消息面，今日央行宣布1年期LPR下调10个基点，降至3.00%；5年期LPR以上下调10个基点，降至 3.50%，为年内首次下调。华创证券指出，央行此举将降低企业融资成本，改善盈利预期，或推动股市 反弹。 此外，国家统计局重申，我国经济长期向好的基本面没有改变，各项宏观政策协同发力，各方面聚力攻 坚、积极应变，创新动能继续成长，经济持续回升具有较多有利条件。券商机构建议，关注内需复苏及 科技高景气领域等。同时，中美关税缓和，叠加中长期资金入市政策，有望进一步提振市场信心。 A500指数ETF（159351）跟踪中证A500指数，由各行业市值较大、流动性较好的500只股票组成，行业 分布均衡，偏向大中盘风格，且新质生产力成分占比较高，为投资者配置A股代表性公司提供了工具。 场外投资者可以通过A500指数ETF联接基金（A类022453；C类022454）布局优质核心资产上行机遇。 5月20日，A股市场放量反弹。到收盘时，沪指报3380.48点，上涨0.38%。场内热门宽基标的A500指数 ETF（159351）结束调整迎来反弹，收盘涨幅达0.62%，小幅溢价0.01%。 盘面上，A500指数E ...

消息面上，5月20日，港股创新药企三生制药与海外辉瑞公司签订重大许可协议，授予辉瑞在全球（不 包括中国内地）独家开发、生产及商业化双抗的权利。根据协议，三生制药将获得12.5亿美元首付款， 并可能获得高达48亿美元的里程碑付款，以及双位数百分比的销售提成。这一交易再次刷新了国产创新 药出海首付款金额纪录。近期创新药行业利好不断。2025年第一季度，中国创新药license-out交易已有 41起，总金额达369.29亿美元，仅3个月已接近2023年全年水平。 相关产品：港股创新药ETF（159567）、创新药ETF（159992） 大而全：创新药ETF（159992）跟踪创新药指数，该指数布局创新药产业链龙头企业，既汇聚全球CXO 龙头企业，又包含国内仿创药企龙头，有望同时受益于AI赋能创新药、国产创新药出海、针对高价创 新药的医保丙类目录出台等。 国元证券认为，上周医药板块受特朗普宣布将推动美国处方药价格与"其他发达国家"对标政策影响，创 新药细分领域出现回调。特朗普提出行政令计划，旨在使美国药价下降30%-80%，并允许患者直接从制 造商购买药物，绕过中间商。然而，分析指出该政策实施难度较大，美国医药市场 ...

第二，大中型药企经营业绩向上趋势明显。创新药企业整体已进入扭亏为盈区间，利润转正后未来几年 将进入非线性地高速增长阶段。同时在产业内，外资药企购买中国创新药品种趋势明显，中国创新药资 产在全球视角下处于显著低估，产业趋势临界点有望到来。 第三，政策端有明显支持的新动作。今年医保谈判时间提前，医保谈判和丙类目录调整同步进行，丙类 目录主要纳入创新程度高的产品，展现国家支持创新药发展、支持商保作为第二支付手段的决心。 上支付宝APP搜：天弘恒生沪深港创新药精选50ETF联接（C类：014565）一键打包三地创新药龙头 股，天弘国证生物医药ETF联接（C类：011041）汇聚医药各行业龙头，有望助您把握本轮医药反弹行 情。 【后市解读：医药板块后市怎么看？—天弘基金】 4月以来，市场风向开始逐渐转向创新药，创新药相关指数在全市场表现靠前。天弘基金认为：基于基 本面和估值的角度，医药是当前全市场性价比非常高的行业。 第一，看好国产创新药的整体机会。总体上创新药产业已经历 4 年下行，前期医保谈判导致预期过度悲 观，目前政策转向空间及需求相对迫。过去几个月，行业内始终有对优化药品集采政策的广泛讨论和相 应的优化方案征求 ...

Group 1 - A-shares indices collectively rose on May 20, with the pharmaceutical sector showing strong performance, particularly in biopharmaceutical ETFs which saw a 2.31% increase and a trading volume exceeding 1.57 billion yuan [1] - Notable stocks included Rongchang Bio, which rose over 9%, and Huaxi Bio and Tigermed, both increasing over 5% [1] - The Innovative Drug ETF also experienced a 2.26% rise, with a trading volume exceeding 2.73 million yuan, and significant gains from stocks like Huahai Pharmaceutical and Hansoh Pharmaceutical [1] Group 2 - Three Life Health signed a licensing agreement with Pfizer for a bispecific antibody product, which includes a non-refundable upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion [1] - The agreement also includes a double-digit percentage sales revenue share based on product sales in authorized regions, and Pfizer will purchase $100 million worth of common stock from Three Life Health [1] - The ASCO annual meeting in 2025 is set to take place in Chicago, recognized as a major oncology academic conference [2] Group 3 - The market is shifting focus from earnings to fundamental changes in the industry and companies as it enters a performance vacuum period in May [3] - The innovative drug sector is expected to be a key investment theme for 2025, with significant research and development progress and resilience against trade wars [3] - The biopharmaceutical industry is anticipated to face significant differentiation by 2025, with the innovative drug sector entering a rapid growth phase, while the vaccine sector remains under pressure due to weak market demand and increased competition [3]

（本文机构观点来自持牌证券机构，不构成任何投资建议，亦不代表平台观点，请投资人独立判断和决 策。） 消息面上，5月贷款市场报价利率（LPR）报价出炉：5年期以上LPR为3.5%，上月为3.6%。1年期LPR 为3%，上月为3.1%。 诚通证券表示，科技与内循环业绩兑现良好，后续有望仍为年内主线。全年来看，自上而下角度，科技 与提振内需仍是年内产业政策主线。自下而上角度，AI产业链国内外产业趋势已经共振。但阶段性而 言，市场4月中旬反弹至今已进入利好兑现阶段，风险偏好或面临回落，红利板块阶段性配置价值更占 优。 国盛证券表示，伴随中长期资金占比提升与短期投机资金退潮，市场波动率显著收敛，企业盈利质量 （ROE）对股价的驱动作用持续强化。当前，资金面阶段性收紧与公募新规的长周期考核要求，进一步 抑制题材炒作惯性，引导资金流向盈利稳定、估值合理的价值型资产。市场逐步回归基本面定价，具备 可持续竞争优势的企业将赢得长期资本青睐。 5月20日，A股三大指数全线飘红，中证A500指数截至发稿涨0.18%，华海药业涨停，上海家化、泰格 医药、信立泰等跟涨。 相关ETF方面，A500指数ETF（159351）小幅走高，截至发 ...

5月20日早盘，中证A500指数小幅高开，截至9：44，涨0.24%，热门ETF中，A500ETF基金 （512050）盘中成交额快速突破1.5亿元，位居同类前列。持仓股中，华海药业、泰格医药等医药股领 涨。 资金流向看，近10个交易日，A500ETF基金（512050）获得资金净流入5.8亿元。 消息面上，5月20日，备受市场关注的5月LPR报价出炉，5年期和1年期利率均下调10BP。5月20日 周二，中国人民银行授权全国银行间同业拆借中心公布，中国1年期贷款市场报价利率（LPR）最新报 3.00%，上次为3.10%；5年期LPR报3.50%，上次为3.60%。此外，工商银行、农业银行、中国银行、建 设银行四大国有行均发布消息，下调人民币存款利率，最大降幅25个基点。其中活期利率下调5个基点 至0.05%；定期整存整取三个月期、半年期、一年期、二年期均下调15个基点，分别为0.65%、0.85%、 0.95%、1.05%；三年期和五年期均下调25个基点，分别至1.25%和1.3%。 每日经济新闻 （责任编辑：张晓波 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立， ...